Skip to main content

What can we do to reduce the risk of another lockdown this Winter?

We all want to avoid another lockdown. We need sustainable public health interventions that will keep Covid-19 cases, hospitalisations and deaths at an acceptable level, and get us through the winter. What could this mean in practice?

1. The most important public health intervention to control Covid-19 is our vaccination programme. This has slowed down in recent months. Also, in effect, it has split into four distinct programmes:

- a programme aimed at people 16 and over. This has almost stopped, with around 10% of adults in the UK still unvaccinated (higher in London).

- a third primary dose programme aimed at people with weak immune systems. This has been poorly planned and implemented by NHS England and has caused a lot of confusion.

- a booster dose programme. This is going OK but could be speeded up to provide more protection for key groups of people before the full onset of winter.

- a programme for 12-15 year olds. This has got off to a very slow start in England. 

Speeding up all these vaccination programmes is essential and is our best defence against Covid-19.


2. Try to reduce social contacts; for example, by asking staff to work from home where possible. The government has been encouraging people to “get back into the office” but I think we should be cautious over the winter.

 

3. Face masks. The government needs to reconsider its policy. In my view, face masks should be required in settings such as shops and public transport. 

 

4. Vaccine mandates / vaccine passports / negative test results. Many European countries require these for entry to higher risk settings such as nightclubs, bars and indoor events. No vaccine is 100% effective but the fact is that an unvaccinated person is much more likely to become infected and transmit infection to others than a vaccinated person. The government has flipped-flopped on this policy (currently against) but have said they may reconsider.


Effective measures now can help bring Covid-19 under control, protect public health, keep pressures on the NHS manageable, and get us through the Winter.

Comments

Post a Comment

Popular posts from this blog

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...
6 comments
Read more

The Hidden Cost of Cheaper NHS Contracts: Losing Community Trust

NHS budgets are under considerable pressure. It is therefore unsurprising that many NHS Integrated Care Boards (ICBs) In England will aim to prioritise price in contract awards, But this approach is a significant threat to community-centred healthcare. While competitive tendering is a legally required, an excessive focus on costs in awarding NHS contracts risks overshadowing key factors such as established community trust, local expertise, and the long-term impact on continuity of care. This shift towards cheaper, often external, commercial providers threatens to cut the links between communities and their local health services. The argument that competitive tendering is solely about legal compliance, and not cost, is undermined by the very nature of such tendering, which by design encourages the lowest bid. This approach risks eroding the social fabric of local healthcare provision, where established relationships and understanding of specific community needs are essential. Establishe...
1 comment
Read more

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...
Post a Comment
Read more